Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation & Amortization - Total (2017 - 2025)

Vanda Pharmaceuticals' Depreciation & Amortization - Total history spans 9 years, with the latest figure at $304000.0 for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization - Total rose 37.56% to $304000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 28.41% increase, with the full-year FY2025 number at $1.1 million, up 28.41% from a year prior.
  • Depreciation & Amortization - Total hit $304000.0 in Q4 2025 for Vanda Pharmaceuticals, up from $301000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization - Total for VNDA hit a ceiling of $345000.0 in Q1 2021 and a floor of $200000.0 in Q3 2023.
  • Historically, Depreciation & Amortization - Total has averaged $273100.0 across 5 years, with a median of $287500.0 in 2022.
  • Biggest five-year swings in Depreciation & Amortization - Total: tumbled 33.11% in 2023 and later surged 39.35% in 2025.
  • Tracing VNDA's Depreciation & Amortization - Total over 5 years: stood at $337000.0 in 2021, then decreased by 15.73% to $284000.0 in 2022, then fell by 27.82% to $205000.0 in 2023, then rose by 7.8% to $221000.0 in 2024, then surged by 37.56% to $304000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization - Total for VNDA at $304000.0 in Q4 2025, $301000.0 in Q3 2025, and $267000.0 in Q2 2025.